Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Terminated 2Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2Plasma cell 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 20Lung Neoplasms 7Neoplasms 5Adenocarcinoma of Lung 5Lymphoma, Large-Cell, Anaplastic 4Neuroblastoma 3Neoplasm Metastasis 3Hematologic Neoplasms 3Granuloma, Plasma Cell 3Melanoma 2Glioblastoma 2Cholangiocarcinoma 2Brain Neoplasms 2Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) 1Thyroid Carcinoma, Anaplastic 1Sarcoma 1Rhabdomyosarcoma 1Pancreatic Neoplasms 1Noonan Syndrome 6 1Non-small Cell Lung Cancer Harboring ROS1 Rearrangement 1Lymphoma, B-Cell 1Carcinoma, Pancreatic Ductal 1Carcinoma 1Adenocarcinoma Of Esophagus 1ALK-positive Non-small Cell Lung Cancer 1ALK-positive NSCLC 1ALK-positive Advanced Tumors 1

Interventions

Cyclophosphamide 87fludarabine 77fludarabine phosphate 45Tacrolimus 45Whole-Body Irradiation 42Mycophenolic Acid 42Busulfan 35Melphalan 32Antilymphocyte Serum 24Methotrexate 23thymoglobulin 22Standard of Care 22Rituximab 22Thiotepa 20Sirolimus 20Azacitidine 20venetoclax 19Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 17Cytarabine 16Bortezomib 16Nivolumab 15Filgrastim 15Specimen Handling 14Dexamethasone 14Blood Specimen Collection 14Cyclosporine 13Surveys and Questionnaires 12Mesna 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Hematologic Neoplasms × ceritinib × Clear all
NCT02186821 2021-04-08

SIGNATURE

Novartis

Phase 2 Terminated
47 enrolled 13 charts
LymphoidOther hematologic neoplasm

Lymphoma, B-Cell, Hematologic Neoplasms

NCT02465528 2019-12-27

Ceritinib Rare Indications Study in ALK+ Tumors

Novartis

Phase 2 Terminated
22 enrolled 16 charts
CNSLymphoidOther hematologic neoplasmPlasma cell

Glioblastoma, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Hematologic Neoplasms

NCT02343679 2017-02-01

Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies

Duke University

Phase 2 Withdrawn
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡